var data={"title":"Adalimumab (including biosimilars of adalimumab): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Adalimumab (including biosimilars of adalimumab): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5570?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=adalimumab-including-biosimilars-of-adalimumab-drug-information\" class=\"drug drug_general\">see &quot;Adalimumab (including biosimilars of adalimumab): Drug information&quot;</a> and <a href=\"topic.htm?path=adalimumab-including-biosimilars-of-adalimumab-patient-drug-information\" class=\"drug drug_patient\">see &quot;Adalimumab (including biosimilars of adalimumab): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708607\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Serious infections:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Patients treated with adalimumab are at increased risk of developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants, such as methotrexate or corticosteroids.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Discontinue adalimumab if a patient develops a serious infection or sepsis. Reported infections include the following:</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Active tuberculosis (TB), including reactivation of latent TB. Patients with TB frequently have presented with disseminated or extrapulmonary disease. Test patients for latent TB before adalimumab use and during therapy. Initiate treatment for latent infection prior to adalimumab use.</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Consider empiric antifungal therapy in patients at risk of invasive fungal infections who develop severe systemic illness.</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Bacterial, viral, and other infections caused by opportunistic pathogens, including Legionella and Listeria.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Carefully consider the risks and benefits of treatment with adalimumab prior to initiating therapy in patients with chronic or recurrent infection.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Monitor patients closely for the development of signs and symptoms of infection during and after treatment with adalimumab, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Malignancy:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Lymphoma and other malignancies, some fatal, have been reported in children and adolescents treated with tumor necrosis factor (TNF)&ndash;blockers, including adalimumab. Postmarketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have been reported in patients treated with TNF-blockers, including adalimumab. These cases have had a very aggressive disease course and have been fatal. The majority of reported TNF-blocker cases have occurred in patients with Crohn disease or ulcerative colitis and the majority were in adolescent and young adult males. Almost all these patients had received treatment with azathioprine or 6-mercaptopurine concomitantly with a TNF-blocker at or prior to diagnosis. It is uncertain whether the occurrence of HSTCL is related to use of a TNF-blocker or a TNF-blocker in combination with these other immunosuppressants.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130499\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Humira;</li>\n      <li>Humira Pediatric Crohns Start;</li>\n      <li>Humira Pen;</li>\n      <li>Humira Pen-Crohns Starter;</li>\n      <li>Humira Pen-Psoriasis Starter</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F855045\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Humira</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F996315\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antirheumatic, Disease Modifying</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Gastrointestinal Agent, Miscellaneous</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Monoclonal Antibody</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Tumor Necrosis Factor (TNF) Blocking Agent</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F996345\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=adalimumab-including-biosimilars-of-adalimumab-drug-information\" class=\"drug drug_general\">see &quot;Adalimumab (including biosimilars of adalimumab): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Crohn disease; moderate to severe; refractory:</b> Humira: Children &ge;6 years and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">17 kg to &lt;40 kg: SubQ: Initial: 80 mg divided into 2 injections (40 mg each) on day 1, then 40 mg administered 2 weeks later (day 15); and then on day 29, begin maintenance dose: 20 mg every other week</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&ge;40 kg: SubQ: Initial: 160 mg divided into 4 injections (40 mg each, administered on one day or as 2 injections per day over 2 consecutive days), then 80 mg (divided into 2 injections [40 mg each] administered on one day) 2 weeks later (day 15); and then on day 29 begin maintenance dose: 40 mg every other week</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Juvenile idiopathic arthritis (JIA):</b> Children &ge;2 years and Adolescents &le;17 years:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 2 to 4 years: Humira:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">10 kg to &lt;15 kg: SubQ: 10 mg every other week</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">15 to &lt;30 kg: SubQ: 20 mg every other week</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;4 years and Adolescents: Humira/Amjevita:</p>\n    <p style=\"text-indent:0em;margin-left:6em;\">15 kg to &lt;30 kg: SubQ: 20 mg every other week</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&ge;30 kg: SubQ: 40 mg every other week</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Ulcerative colitis; moderate to severe, refractory:</b> Limited data available: Children and Adolescents: SubQ: Initial: 100 mg/m<sup>2</sup> (maximum dose: 160 mg/dose), then 50 mg/m<sup>2</sup> (maximum dose: 80 mg/dose) 2 weeks later; then on day 29, begin maintenance therapy: 25 mg/m<sup>2</sup> every other week (maximum dose: 40 mg/dose) (Turner 2012). <b>Note:</b> Trials performed with Humira product.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Uveitis:</b> Limited data available; dosing regimens variable; <b>Note:</b> Trials performed with Humira product.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Body surface area-directed dosing: Children &ge;4 years and Adolescents: SubQ: 24 or 40 mg/m<sup>2</sup> every 2 weeks; maximum dose 40 mg/dose (Gallagher 2007; Simonini 2011). Dosing based on one prospective trial comparing 24 mg/m<sup>2</sup>/dose every 2 weeks of adalimumab (n=16, ages 6 to 12 years) to infliximab (n=17, ages 5 to 13 years) and on a retrospective trial of biologic response modifiers, including five patients who received adalimumab at 40 mg/m<sup>2</sup>/dose every 2 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Weight-directed dosing: Children &ge;2 years and Adolescents (Biester 2007; Ramanan 2017; Sens 2012; Tynjala 2008):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&lt;30 kg: SubQ: 20 mg every other week</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&ge;30 kg: SubQ: 40 mg every other week</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Ankylosing spondylitis:</b> Humira, Amjevita: SubQ: 40 mg every other week</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Crohn disease:</b> Humira, Amjevita: SubQ: Initial: 160 mg divided into 4 doses (given as 4 injections on day 1 or as 2 injections per day over 2 consecutive days), then 80 mg 2 weeks later (day 15); maintenance: 40 mg every other week beginning day 29; <b>Note:</b> Some patients may require 40 mg every week as maintenance therapy (Lichtenstein 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hidradenitis suppurativa</b>: Humira: SubQ: Initial: 160 mg (given as four 40 mg injections on day 1 or given as two 40 mg injections per day over 2 consecutive days), then 80 mg 2 weeks later (day 15); maintenance: 40 mg every week beginning day 29</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Plaque psoriasis:</b> Humira, Amjevita: SubQ: Initial: 80 mg as a single dose; maintenance: 40 mg every other week beginning 1 week after initial dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Psoriatic arthritis:</b> Humira, Amjevita: SubQ: 40 mg every other week</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Rheumatoid arthritis:</b> Humira, Amjevita: SubQ: 40 mg every other week; may be administered with other DMARDs; patients not taking methotrexate may increase dose to 40 mg every week</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Ulcerative colitis:</b> Humira, Amjevita: SubQ: Initial: 160 mg divided into 4 doses (given as 4 injections on day 1 or as 2 injections daily over 2 consecutive days), then 80 mg 2 weeks later (day 15); maintenance: 40 mg every other week beginning day 29. <b>Note:</b> Only continue maintenance dose in patients demonstrating clinical remission by 8 weeks (day 57) of therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Uveitis: </b>Humira: SubQ: Initial: 80 mg as a single dose; maintenance: 40 mg every other week beginning 1 week after initial dose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> Children, Adolescents, and Adults: There are no dosage adjustments provided in the manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> Children, Adolescents, and Adults: There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130481\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Pen-injector Kit, Subcutaneous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Humira Pen: 40 mg/0.8 mL (1 ea) [contains polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Humira Pen-Crohns Starter: 40 mg/0.8 mL (1 ea) [contains polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Humira Pen-Psoriasis Starter: 40 mg/0.8 mL (1 ea) [contains polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Prefilled Syringe Kit, Subcutaneous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Humira: 10 mg/0.2 mL (1 ea); 20 mg/0.4 mL (1 ea); 40 mg/0.8 mL (1 ea) [contains polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Humira Pediatric Crohns Start: 40 mg/0.8 mL (1 ea) [contains polysorbate 80]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130468\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F48944172\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amjevita (adalimumab-atto): FDA approved September 2016; anticipated availability is currently unknown. Amjevita is approved as biosimilar to Humira. Consult the prescribing information for additional information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cyltezo (adalimumab-adbm): FDA approved August 2017; anticipated availability is currently unknown. Cyltezo is approved as biosimilar to Humira. Information pertaining to this product within the monograph is pending revision. Consult the prescribing information for additional information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7874545\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Amjevita (adalimumab-atto): <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM524671.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn//CovC0x0ey2BbNY46aAsKLtMA9hl0dCA7mc+XSdGLuTQ==&amp;TOPIC_ID=13077\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM524671.pdf</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cyltezo (adalimumab-adbm): <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761058lbl.pdf#page=30&amp;token=HNdLXLcVXpHUrLNXCtoYCMSmrnVAHuFMtiGTuJhMMPNAmdSMssumQqWLy78IYO3zLFPDGdWywWJjws2eDoyVBErjDUJQ/P0PgF7PF065dX/NMQQKcMfUEqFqO8fgEz4G&amp;TOPIC_ID=13077\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761058lbl.pdf#page=30</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Humira: <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125057s403lbl.pdf#page=53&amp;token=MXTHlzu2f6jTWWasC0z83Oqnl/vC7h0u9788sfpHU/9DYEXqd9LJBjpAIOvA9LGLnofw3o4u/InzNpYdrkcRb9B1eeQ6PzSt008vbfVDQLbAhIAxTDmhSOajgaKp36Up&amp;TOPIC_ID=13077\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125057s403lbl.pdf#page=53</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F996347\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">For SubQ injection into thigh or lower abdomen (avoid areas within 2 inches of navel); rotate injection sites. May leave at room temperature for ~15 to 30 minutes prior to use; do not remove cap or cover while allowing product to reach room temperature. Do not use if solution is discolored or contains particulate matter. Do not administer to skin which is red, tender, bruised, or hard. Prefilled pens and syringes are available for use by patients (self-administration); the Humira vial is intended for institutional use only and does not contain a preservative; discard unused portion.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130495\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F) in original container to protect from light; do not freeze. Do not use if frozen even if it has been thawed. Do not store in extreme heat or cold. If needed, may be stored at room temperature up to a maximum of 25&deg;C (77&deg;F) for up to 14 days; discard if not used within 14 days.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F996316\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) alone or in combination with methotrexate (Humira: FDA approved in ages 2 to 17 years weighing &ge;10 kg; Amjevita: FDA approved in ages 4 to 17 years weighing &ge;15 kg); treatment and maintenance of remission in patients with moderately to severely active Crohn disease with inadequate response to conventional treatment or patients who have lost response to or are intolerant of infliximab (Humira: FDA approved ages &ge;6 years and adults), Amjevita: FDA approved in adults); moderately to severely active rheumatoid arthritis (RA) alone or in combination with methotrexate or other nonbiologic, disease-modifying antirheumatic drugs (DMARDs) (Humira, Amjevita: FDA approved in adults); active psoriatic arthritis alone or in combination with nonbiologic DMARDs (Humira, Amjevita: FDA approved in adults); active ankylosing spondylitis (Humira, Amjevita: FDA approved in adults); treatment of moderate to severe chronic plaque psoriasis when systemic therapy is required and other agents are less appropriate (Humira, Amjevita: FDA approved in adults); and treatment and maintenance of remission in patients with moderately to severely active ulcerative colitis unresponsive to immunosuppressants (Humira, Amjevita: FDA approved in adults). <b>Note:</b> Efficacy in ulcerative colitis patients who are intolerant or no longer responsive to other TNF blockers has not been established. Treatment of moderate to severe hidradenitis suppurativa (Humira: FDA approved in adults); treatment of noninfectious intermediate, posterior, and panuveitis (Humira FDA approved in adults). Has also been used in children with idiopathic or JIA-associated uveitis and chronic uveitis.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">\n      <b>Note:</b> Amjevita (adalimumab-atto) is approved as a biosimilar agent. Approved uses may vary (consult product labeling).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130521\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Adalimumab may be confused with sarilumab.</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Humira may be confused with Humulin, Humalog</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Humira Pen may be confused with HumaPen Memoir (used with HumaLOG)</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130519\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Atrial fibrillation, cardiac arrest, cardiac arrhythmia, chest pain, coronary artery disease, deep vein thrombosis, hypertension, hypertensive encephalopathy, myocardial infarction, palpitations, pericardial effusion, pericarditis, peripheral edema, subdural hematoma, syncope, tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Confusion, headache, myasthenia, paresthesia, torso pain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Cellulitis, erysipelas, skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Dehydration, hypercholesterolemia, hyperlipidemia, ketosis, menstrual disease, parathyroid disease</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain, cholecystitis, cholelithiasis, diverticulitis, esophagitis, gastrointestinal hemorrhage, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Cystitis, hematuria, pelvic pain, urinary tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Adenoma, agranulocytosis, carcinoma (including breast, gastrointestinal, skin, urogenital), malignant lymphoma, malignant melanoma, paraproteinemia, polycythemia, positive ANA titer</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Hepatic necrosis, increased serum alkaline phosphatase</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Hypersensitivity reaction (more common in children)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immunologic: Antibody development (significance unknown)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Herpes simplex infection, herpes zoster, infection (children and adolescents), sepsis, serious infection (including dental caries, gastroenteritis, rotavirus, varicella)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Injection site reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia (plaque psoriasis), arthritis, arthropathy, back pain, bone disease, bone fracture, increased creatine phosphokinase, limb pain, muscle cramps, myasthenia, osteonecrosis, septic arthritis, synovitis, tendon disease, tremor</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Cataract</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Nephrolithiasis, pyelonephritis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Asthma, bronchospasm, dyspnea, flu-like symptoms, pharyngitis (juvenile idiopathic arthritis), pleural effusion, pneumonia, respiratory depression, sinusitis, tuberculosis (including reactivation of latent infection; disseminated, miliary, lymphatic, peritoneal, and pulmonary), upper respiratory tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Abnormal healing, accidental injury, postoperative complication (infection)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Abscess (limb, perianal), alopecia, anal fissure, anaphylactoid reaction, anaphylaxis, angioedema, aplastic anemia, appendicitis, bacterial infection, basal cell carcinoma, cardiac failure, cerebrovascular accident, cervical dysplasia, circulatory shock, cytopenia, dermal ulcer, endometrial hyperplasia, erythema multiforme, fixed drug eruption, fulminant necrotizing fasciitis, fungal infection, Guillain-Barr&eacute; syndrome, hepatic failure, hepatitis B (reactivation), hepatosplenic T-cell lymphomas (children, adolescents, and young adults), hepatotoxicity (idiosyncratic) (Chalasani 2014), histoplasmosis, hypersensitivity angiitis, increased serum transaminases, interstitial pulmonary disease (eg, pulmonary fibrosis), intestinal obstruction, intestinal perforation, leukemia, leukopenia, liver metastases, lupus-like syndrome, lymphadenopathy, lymphocytosis, malignant neoplasm of ovary, meningitis (viral), Merkel cell carcinoma, multiple sclerosis, mycobacterium avium complex, myositis (children and adolescents), neutropenia, optic neuritis, pancreatitis, pancytopenia, protozoal infection, psoriasis (including new onset, palmoplantar, pustular, or exacerbation), pulmonary embolism, respiratory failure, sarcoidosis, septic shock, skin granuloma (annulare; children and adolescents), Stevens-Johnson syndrome, streptococcal pharyngitis (children and adolescents), systemic lupus erythematosus, testicular neoplasm, thrombocytopenia, vasculitis (systemic), viral infection</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130486\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">There are no contraindications listed in the manufacturer's US labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Known hypersensitivity to adalimumab or any component of the formulation; severe infection (eg, sepsis, tuberculosis, opportunistic infection); moderate-to-severe heart failure (NYHA class III/IV)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130471\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylaxis/hypersensitivity reactions: May rarely cause hypersensitivity, anaphylaxis, anaphylactoid reactions, or angioneurotic edema; medications for the treatment of hypersensitivity reactions should be available for immediate use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Autoimmune disorder: Positive antinuclear antibody titers have been detected in patients (with negative baselines). Rare cases of autoimmune disorder, including lupus-like syndrome, have been reported; monitor and discontinue if symptoms develop.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Demyelinating disease: Rare cases of new-onset or exacerbation of demyelinating disorders (eg, multiple sclerosis, optic neuritis, peripheral demyelinating disease, including Guillain-Barr&eacute; syndrome) have been reported; there is a known association between intermediate uveitis and central demyelinating disorders. Consider discontinuing use in patients who develop peripheral or central nervous system demyelinating disorders during treatment. Use with caution in patients with preexisting or recent onset central or peripheral nervous system demyelinating disorders.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Heart failure: Worsening and new-onset heart failure (HF) has been reported with adalimumab and other TNF blockers. Use with caution in patients with HF or decreased left ventricular function. In a scientific statement from the American Heart Association, TNF blockers have been determined to be agents that may either cause direct myocardial toxicity or exacerbate underlying myocardial dysfunction (magnitude: major) (AHA [Page 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hematologic disorders: Rare cases of pancytopenia and aplastic anemia have been reported with TNF-blockers. Patients must be advised to seek medical attention if they develop signs and symptoms suggestive of blood dyscrasias; discontinue if significant hematologic abnormalities are confirmed. Use with caution in patients with a history of significant hematologic abnormalities.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatitis B: Rare reactivation of hepatitis B (HBV) has occurred in chronic carriers of the virus, usually in patients receiving concomitant immunosuppressants (some have been fatal); evaluate for HBV prior to initiation in all patients. Monitor during and for several months following discontinuation of treatment in HBV carriers; interrupt therapy if reactivation occurs and treat appropriately with antiviral therapy; if resumption of therapy is deemed necessary, exercise caution and monitor patient closely.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infections: <b>[US Boxed Warning]: Patients receiving adalimumab are at increased risk for serious infections which may result in hospitalization and/or fatality; infections usually developed in patients receiving concomitant immunosuppressive agents (eg, methotrexate, corticosteroids) and may present as disseminated (rather than local) disease. Active tuberculosis (including reactivation of latent tuberculosis), invasive fungal (including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, and pneumocystosis) and bacterial, viral or other opportunistic infections (including legionellosis and listeriosis) have been reported. Monitor closely for signs/symptoms of infection during and after treatment. Discontinue for serious infection or sepsis. Consider risks versus benefits prior to initiating therapy in patients with chronic or recurrent infection. Consider empiric antifungal therapy in patients who are at risk for invasive fungal infections who develop severe systemic illness. </b>Caution should be exercised when considering use in the elderly, patients with a history of an opportunistic infection, patients taking concomitant immunosuppressants (eg, corticosteroids, methotrexate), or in patients with conditions that predispose them to infections (eg, advanced or poorly controlled diabetes) or residence/travel in areas of endemic tuberculosis or mycoses (blastomycosis, coccidioidomycosis, histoplasmosis), or with latent infections. Do not initiate adalimumab in patients with an active infection, including clinically important localized infection. Patients who develop a new infection while undergoing treatment should be monitored closely.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Malignancy: <b>[US Boxed Warning]: Lymphoma and other malignancies (some fatal) have been reported in children and adolescents receiving TNF-blocking agents, including adalimumab. </b>Half of the malignancies reported in children and adolescents were lymphomas (Hodgkin and non-Hodgkin) while other cases varied and included rare malignancies usually associated with immunosuppression and malignancies not typically observed in this population. Most patients were receiving concomitant immunosuppressants. <b>[US Boxed Warning]: Hepatosplenic T-cell lymphoma (HSTCL), a rare T-cell lymphoma, has been reported (some fatal) primarily in patients with Crohn disease or ulcerative colitis treated with adalimumab and who received concomitant azathioprine or mercaptopurine; reports occurred predominantly in adolescent and young adult males.</b> The impact of adalimumab on the development and course of malignancy is not fully defined. Compared to the general population, an increased risk of lymphoma has been noted in clinical trials; however, rheumatoid arthritis alone has been previously associated with an increased rate of lymphoma and leukemia. A higher incidence of nonmelanoma skin cancers was noted in adalimumab-treated patients (0.7/100 patient years), when compared to the control group (0.2/100 patient years).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tuberculosis: <b>[US Boxed Warnings]: </b><b>Active tuberculosis (disseminated or extrapulmonary), including reactivation of latent tuberculosis, has been reported in patients receiving adalimumab. Evaluate patients for tuberculosis risk factors and latent tuberculosis infection (with a skin test) prior to and during therapy. Treatment for latent tuberculosis should be initiated before use. Patients with initial negative tuberculin skin tests should receive continued monitoring for tuberculosis during and after treatment.</b> Consider antituberculosis treatment if an adequate course of treatment cannot be confirmed in patients with a history of latent or active tuberculosis or with risk factors despite negative skin test. Some patients who tested negative prior to therapy have developed active infection; tests for latent tuberculosis infection may be falsely negative while on adalimumab therapy. Use with caution in patients who have traveled to or resided in regions where tuberculosis is endemic. Monitor for signs and symptoms of tuberculosis in all patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Infection and malignancy has been reported at a higher incidence; use caution in elderly patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Malignancies have been reported among children and adolescents.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Surgery patients: Limited experience with patients undergoing surgical procedures while on therapy; consider long half-life with planned procedures. Monitor closely for infection.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Latex: The packaging (needle cover of prefilled syringe and autoinjector) may contain latex.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immunizations: Patients should be brought up to date with all immunizations before initiating therapy; live vaccines should not be given concurrently. There are no data available concerning the effects of therapy on vaccination or secondary transmission of live vaccines in patients receiving therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25819722\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Postmarketing reports of lymphomas and other malignancies were primarily in pediatric patients with Crohn disease or ulcerative colitis treated with adalimumab and who received concomitant azathioprine or mercaptopurine; reports occurred predominantly in adolescent and young adult males. As compared to the general population, an increased risk of lymphoma has been noted in clinical trials; however, rheumatoid arthritis has been previously associated with an increased rate of lymphoma. In an analysis of children and adolescents who had received TNF-blockers (etanercept and infliximab), the FDA identified 48 cases of malignancy. Of the 48 cases, ~50% were lymphomas (eg, Hodgkin and non-Hodgkin lymphoma). Other malignancies, such as leukemia, melanoma, and solid organ tumors were reported; malignancies rarely seen in children (eg, leiomyosarcoma, hepatic malignancies, and renal cell carcinoma) were also observed. Of note, most of these cases (88%) were receiving other immunosuppressive medications (eg, azathioprine and methotrexate). The role of TNF-blockers in the development of malignancies in children cannot be excluded. The FDA also reviewed 147 postmarketing reports of leukemia (including acute myeloid leukemia, chronic lymphocytic leukemia, and chronic myeloid leukemia) in patients (children and adults) using TNF-blockers. Average onset time to development of leukemia was within the first 1 to 2 years of TNF-blocker initiation.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Reactivation of TB has been reported in pediatric patients receiving biologic response modifiers (infliximab and etanercept); prior to therapy, patients with no TB risk factors should be screened for latent TB infection (LTBI) with an age appropriate test (ie, &lt;5 years of age: tuberculin skin test, and &ge;5 years of age: IGRA [interferon gamma release assay]); if any TB risk factors are present or symptoms, both LTBI screening tests should be performed (AAP [Davis 2016])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298685\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130475\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13077&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Abatacept: Anti-TNF Agents may enhance the adverse/toxic effect of Abatacept. An increased risk of serious infection during concomitant use has been reported. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anakinra: Anti-TNF Agents may enhance the adverse/toxic effect of Anakinra. An increased risk of serious infection during concomitant use has been reported. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Belimumab: Monoclonal Antibodies may enhance the adverse/toxic effect of Belimumab. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Canakinumab: Anti-TNF Agents may enhance the adverse/toxic effect of Canakinumab. Specifically, the risk for serious infections and/or neutropenia may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Certolizumab Pegol: Anti-TNF Agents may enhance the immunosuppressive effect of Certolizumab Pegol. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): Adalimumab may decrease the serum concentration of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">InFLIXimab: Adalimumab may enhance the immunosuppressive effect of InFLIXimab. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rilonacept: Anti-TNF Agents may enhance the adverse/toxic effect of Rilonacept. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Theophylline Derivatives: Adalimumab may decrease the serum concentration of Theophylline Derivatives. <b> Exceptions: </b>Dyphylline.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiopurine Analogs: Anti-TNF Agents may enhance the adverse/toxic effect of Thiopurine Analogs. Specifically, the risk for T-cell non-Hodgkin's lymphoma (including hepatosplenic T-cell lymphoma) may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May enhance the immunosuppressive effect of Anti-TNF Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Anti-TNF Agents may enhance the adverse/toxic effect of Tofacitinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vedolizumab: Anti-TNF Agents may enhance the adverse/toxic effect of Vedolizumab. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Warfarin: Adalimumab may decrease the serum concentration of Warfarin. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130488\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adalimumab crosses the placenta and can be detected in cord blood at birth at concentrations higher than those in the maternal serum. In one study of pregnant women with inflammatory bowel disease, adalimumab was found to be measurable in a newborn for up to 11 weeks following delivery. Maternal doses of adalimumab were 40 mg every other week (n=9) or 40 mg weekly (n=1) and the last dose was administered 0.14 to 8 weeks prior to delivery (median 5.5 weeks) (Mahadevan 2013). If therapy for inflammatory bowel disease is needed during pregnancy, adalimumab should be discontinued before 30 weeks gestation in order to decrease exposure to the newborn. In addition, the administration of live vaccines should be postponed until anti-TNF concentrations in the infant are negative (Habal 2012; Mahadeven 2013; Zelinkova 2013).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Women exposed to adalimumab during pregnancy for the treatment of an autoimmune disease (eg, inflammatory bowel disease) may contact the OTIS Autoimmune Diseases Study at 877-311-8972.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F996349\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor improvement of symptoms and physical function assessments. Latent TB screening prior to initiating and during therapy; signs/symptoms of infection (prior to, during, and following therapy); CBC with differential; signs/symptoms/worsening of heart failure; LFTs at baseline; HBV screening prior to initiating (all patients), HBV carriers (during and for several months following therapy); signs and symptoms of hypersensitivity reaction; symptoms of lupus-like syndrome; signs/symptoms of malignancy (eg, splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss), including periodic skin examination.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130470\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Adalimumab is a recombinant monoclonal antibody that binds to human tumor necrosis factor alpha (TNF-alpha), thereby interfering with binding to TNF&alpha; receptor sites and subsequent cytokine-driven inflammatory processes. Elevated TNF levels in the synovial fluid are involved in the pathologic pain and joint destruction in immune-mediated arthritis. Adalimumab decreases signs and symptoms of psoriatic arthritis, rheumatoid arthritis, and ankylosing spondylitis. It inhibits progression of structural damage of rheumatoid and psoriatic arthritis. Reduces signs and symptoms and maintains clinical remission in Crohn disease and ulcerative colitis; reduces epidermal thickness and inflammatory cell infiltration in plaque psoriasis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130485\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: 4.7 to 6 L; Synovial fluid concentrations: 31% to 96% of serum </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Absolute: 64% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Terminal: ~2 weeks (range: 10 to 20 days) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: SubQ: 131 &plusmn; 56 hours </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130487\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Pen-injector Kit</b> (Humira Pen Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg/0.8 mL (1): $2,923.22</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Pen-injector Kit</b> (Humira Pen-Crohns Starter Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg/0.8 mL (1): $2,923.22</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Pen-injector Kit</b> (Humira Pen-Psoriasis Starter Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg/0.8 mL (1): $2,923.22</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Prefilled Syringe Kit</b> (Humira Pediatric Crohns Start Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg/0.8 mL (1): $2,923.22</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Prefilled Syringe Kit</b> (Humira Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/0.2 mL (1): $2,923.22</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg/0.4 mL (1): $2,923.22</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg/0.8 mL (1): $2,923.22</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130489\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Amgevita (AT);</li>\n      <li>Humira (AE, AR, AT, AU, BB, BE, BG, BH, BR, CH, CL, CN, CO, CR, CY, CZ, DE, DK, DO, EC, EE, EG, ES, FI, FR, GB, GR, GT, HK, HN, HR, HU, IE, IL, IQ, IR, IS, IT, JO, JP, KR, KW, LB, LT, LU, LV, LY, MT, MX, MY, NI, NL, NO, NZ, OM, PA, PE, PH, PL, PT, PY, QA, RO, RU, SA, SE, SG, SI, SK, SV, SY, TR, TW, UA, UY, VE, VN, YE, ZA);</li>\n      <li>Solymbic (AT);</li>\n      <li>Trudexa (BE, BG, CH, CZ, DE, DK, EE, FI, FR, GB, GR, IT, NL, NO, PT, RU, SE, SK, TR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. Pediatrics. 1986;77(4):593-597.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Amjevita (adalimumab) [prescribing information]. Thousand Oaks, CA: Amgen Inc; September 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ayala RS, Groh BP, Robbins LM, et al, &quot;The Addition of Injectable Lidocaine to Adalimumab Results in Decreased Injection Site Pain and Increased Acceptance of Therapy,&quot; 2008, American College of Rheumatology Annual Scientific Meeting, San Francisco, CA (poster).</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Beukelman T, Patkar NM, Saag KG, et al, &quot;2011 American College of Rheumatology Recommendations for the Treatment of Juvenile Idiopathic Arthritis: Initiation and Safety Monitoring of Therapeutic Agents for the Treatment of Arthritis and Systemic Features,&quot; <i>Arthritis Care Res (Hoboken)</i>, 2011, 63(4):465-82.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/adalimumab-including-biosimilars-of-adalimumab-pediatric-drug-information/abstract-text/21452260/pubmed\" target=\"_blank\" id=\"21452260\">21452260</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Biester S, Deuter C, Michels H, et al, &quot;Adalimumab in the Therapy of Uveitis in Childhood,&quot; <i>Br J Ophthalmol</i>, 2007, 91(3):319-24.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/adalimumab-including-biosimilars-of-adalimumab-pediatric-drug-information/abstract-text/17035274/pubmed\" target=\"_blank\" id=\"17035274\">17035274</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. MMWR Morb Mortal Wkly Rep. 1984;33(14):198-199 <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC). CDC clinical reminder: insulin pens must never be used for more than one person. Centers for Disease Control and Prevention Web site. Available at <a href=\"http://www.cdc.gov/injectionsafety/clinical-reminders/insulin-pens.html\" target=\"_blank\">http://www.cdc.gov/injectionsafety/clinical-reminders/insulin-pens.html</a>. Updated January 5, 2012. Accessed January 9, 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Davies HD, Committee on Infectious Disease. Infectious complications with the use of biologic response modifiers in infants and children. <i>Pediatrics</i>. 2016;138(2):e20161209.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/adalimumab-including-biosimilars-of-adalimumab-pediatric-drug-information/abstract-text/27432853/pubmed\" target=\"_blank\" id=\"27432853\">27432853</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Furst DE, Keystone EC, Kirkham B, et al, &quot;Updated Consensus Statement on Biological Agents for the Treatment of Rheumatic Diseases, 2008,&quot; <i>Ann Rheum Dis</i>, 2008, 67 Suppl 3:iii2-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/adalimumab-including-biosimilars-of-adalimumab-pediatric-drug-information/abstract-text/19022808 /pubmed\" target=\"_blank\" id=\"19022808 \">19022808 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gallagher M, Quinones K, Cervantes-Casta&ntilde;eda RA, Yilmaz T, Foster CS. Biological response modifier therapy for refractory childhood uveitis.<i> Br J Ophthalmol</i>. 2007t;91(10):1341-1344.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/adalimumab-including-biosimilars-of-adalimumab-pediatric-drug-information/abstract-text/17556427 /pubmed\" target=\"_blank\" id=\"17556427 \">17556427 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Habal FM and Huang VW, &quot;Review Article: A Decision-Making Algorithm For the Management of Pregnancy in the Inflammatory Bowel Disease Patient,&quot; <i>Aliment Pharmacol Ther</i>, 2012, 35(5):501-15.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/adalimumab-including-biosimilars-of-adalimumab-pediatric-drug-information/abstract-text/22221203/pubmed\" target=\"_blank\" id=\"22221203\">22221203</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Humira (adalimumab) [prescribing information]. North Chicago, IL: AbbVie Inc; April 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hyams JS, Griffiths A, Markowitz J, et al, &quot;Safety and Efficacy of Adalimumab for Moderate to Severe Crohn's Disease in Children,&quot; <i>Gastroenterology</i>, 2012, 143(2):365-74.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/adalimumab-including-biosimilars-of-adalimumab-pediatric-drug-information/abstract-text/22562021/pubmed\" target=\"_blank\" id=\"22562021\">22562021</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. Contact Dermatitis. 2002;47:313.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lichtenstein GR, Hanauer SB, and Sandborn WJ, &quot;Management of Crohn's Disease in Adults,&quot; <i>Am J Gastroenterol</i>, 2009, 104(2):465-83.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/adalimumab-including-biosimilars-of-adalimumab-pediatric-drug-information/abstract-text/19174807/pubmed\" target=\"_blank\" id=\"19174807\">19174807</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lovell DJ, Ruperto N, Goodman S, et al, &quot;Adalimumab With or Without Methotrexate in Juvenile Rheumatoid Arthritis,&quot; <i>N Engl J Med</i>, 2008, 359(8):810-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/adalimumab-including-biosimilars-of-adalimumab-pediatric-drug-information/abstract-text/18716298/pubmed\" target=\"_blank\" id=\"18716298\">18716298</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. Contact Dermatitis. 2000;43:172.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mahadevan U, Wolf DC, Dubinsky M, et al, &quot;Placental Transfer of Anti-Tumor Necrosis Factor Agents in Pregnant Patients With Inflammatory Bowel Disease,&quot; <i>Clin Gastroenterol Hepatol</i>, 2013, 11(3):286-92.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/adalimumab-including-biosimilars-of-adalimumab-pediatric-drug-information/abstract-text/23200982/pubmed\" target=\"_blank\" id=\"23200982\">23200982</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ramanan AV, Dick AD, Jones AP. Adalimumab plus methotrexate for uveitis in juvenile idiopathic arthritis. <i>N Engl J Med</i>. 2017;376(17):1637-1646.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/adalimumab-including-biosimilars-of-adalimumab-pediatric-drug-information/abstract-text/28445659/pubmed\" target=\"_blank\" id=\"28445659\">28445659</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rosh JR, Lerer T, Markowitz J, et al, &quot;Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in Pediatric Crohn's Disease,&quot; <i>Am J Gastroenterol</i>, 2009, 104(12):3042-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/adalimumab-including-biosimilars-of-adalimumab-pediatric-drug-information/abstract-text/19724267/pubmed\" target=\"_blank\" id=\"19724267\">19724267</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sen ES, Sharma S, Hinchcliffe A, et al, &quot;Use of Adalimumab in Refractory Non-infectious Childhood Chronic Uveitis: Efficacy in Ocular Disease - a Case Cohort Interventional Study,&quot; <i>Rheumatology (Oxford)</i>, 2012, 51(12):2199-203.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/adalimumab-including-biosimilars-of-adalimumab-pediatric-drug-information/abstract-text/22923752/pubmed\" target=\"_blank\" id=\"22923752\">22923752</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. Lancet. 1995;345(8980):1312-1313.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Simonini G, Taddio A, Cattalini M, et al, &quot;Prevention of Flare Recurrences in Childhood-Refractory Chronic Uveitis: An Open-Label Comparative Study of Adalimumab Versus Infliximab,&quot; <i>Arthritis Care Res (Hoboken)</i>, 2011, 63(4):612-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/adalimumab-including-biosimilars-of-adalimumab-pediatric-drug-information/abstract-text/21452272/pubmed\" target=\"_blank\" id=\"21452272\">21452272</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Turner D, Levine A, Escher JC, et al. Management of pediatric ulcerative colitis: joint ECCO and ESPGHAN evidence-based consensus guidelines. <i>J Pediatr Gastroenterol Nutr</i>. 2012;55(3):340-361.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/adalimumab-including-biosimilars-of-adalimumab-pediatric-drug-information/abstract-text/22773060 /pubmed\" target=\"_blank\" id=\"22773060 \">22773060 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tynj&auml;l&auml; P, Kotaniemi K, Lindahl P, et al, &quot;Adalimumab in Juvenile Idiopathic Arthritis-Associated Chronic Anterior Uveitis,&quot; <i>Rheumatology (Oxford)</i>, 2008, 47(3):339-44.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/adalimumab-including-biosimilars-of-adalimumab-pediatric-drug-information/abstract-text/18238789/pubmed\" target=\"_blank\" id=\"18238789\">18238789</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zelinkova Z, van der Ent C, Bruin KF, et al, &quot;Effects of Discontinuing Anti-Tumor Necrosis Factor Therapy During Pregnancy on the Course of Inflammatory Bowel Disease and Neonatal Exposure,&quot; <i>Clin Gastroenterol Hepatol</i>, 2013, 11(3):318-21.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/adalimumab-including-biosimilars-of-adalimumab-pediatric-drug-information/abstract-text/23103819/pubmed\" target=\"_blank\" id=\"23103819\">23103819</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13077 Version 148.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708607\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F130499\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F855045\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F996315\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F996345\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F130481\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F130468\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F48944172\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F7874545\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F996347\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F130495\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F996316\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F130521\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F130519\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F130486\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F130471\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F25819722\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298685\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F130475\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F130488\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F996349\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F130470\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F130485\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F130487\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F130489\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13077|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=adalimumab-including-biosimilars-of-adalimumab-drug-information\" class=\"drug drug_general\">Adalimumab (including biosimilars of adalimumab): Drug information</a></li><li><a href=\"topic.htm?path=adalimumab-including-biosimilars-of-adalimumab-patient-drug-information\" class=\"drug drug_patient\">Adalimumab (including biosimilars of adalimumab): Patient drug information</a></li></ul></div></div>","javascript":null}